NOVAVAX INC (NVAX) Stock
1 member of Congress disclosed 2 trades in NVAX since 2020: 1 purchase and 1 sale, most recently Pat Roberts (sale, Oct 13, 2020). 8 of the hedge funds AlphaScala tracks reported NVAX in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $53.23M.
Which members of Congress traded NOVAVAX INC (NVAX)?
Most recent: Pat Roberts (sale, Oct 13, 2020); records start Aug 17, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Pat Roberts R-KS · Senate | 2020-10-13 | sale | $1k – $15k |
| Pat Roberts R-KS · Senate | 2020-08-17 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all NVAX political trades →Which hedge funds own NVAX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 5.65M | $53.23M | -27% |
| Coatue Management Philippe Laffont | 3.84M | $36.14M | n/a |
| Millennium Management Israel Englander | 1.77M | $16.66M | -54% |
| Citadel Ken Griffin | 1.70M | $15.97M | +51% |
| Point72 Steve Cohen | 664K | $6.26M | -56% |
| Marshall Wace | 653K | $6.15M | -44% |
| Renaissance Technologies Jim Simons (founder) | 502K | $4.73M | +1% |
| Hussman Investment Trust John Hussman | 105K | $1.14M | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →NVAX price chart
Powered by TradingViewWhat does NOVAVAX INC do?
Novavax Inc. is a biotechnology company that engages in the discovery, development, and commercialization of recombinant vaccines to protect against serious infectious diseases. It specializes in protein-based vaccine platforms, including its proprietary Matrix-M adjuvant technology, which enhances immune responses. The company focuses on vaccines for respiratory diseases, such as its Nuvaxovid COVID-19 vaccine, and advances a pipeline targeting influenza, combination COVID-influenza, and other pathogens. Novavax Inc. operates through strategic partnerships with global pharmaceutical leaders like Pfizer and Sanofi for manufacturing, distribution, and milestone-based collaborations, enabling broader market reach in the United States, Europe, and internationally. Its recombinant nanoparticle vaccine approach distinguishes it in the health technology sector, emphasizing innovative solutions for pandemic preparedness and routine immunization needs. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax Inc. plays a key role in the biotechnology industry by addressing unmet needs in infectious disease prevention.